Merck & Co., Inc. (FRA:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 174.12B |
| Revenue (ttm) | 59.14B |
| Net Income (ttm) | 16.13B |
| Shares Out | n/a |
| EPS (ttm) | 6.36 |
| PE Ratio | 10.80 |
| Forward PE | 8.78 |
| Dividend | 2.93 (4.31%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 2,478 |
| Average Volume | 4,623 |
| Open | 68.50 |
| Previous Close | 68.30 |
| Day's Range | 67.80 - 69.70 |
| 52-Week Range | 65.50 - 125.60 |
| Beta | n/a |
| RSI | 50.23 |
| Earnings Date | Jul 29, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
New On The Block Byron Allen 's Allen Media Group has hired Moelis & Company to explore a sale of its TV stations across 21 markets. The company spent over $1 billion acquiring Big Four network affili...
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech (NASDAQ: ALVO) on Thursday collaborated with Dr. Reddy's Laboratories Ltd. (NYSE: RDY) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for gl...
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Merck gains U.S. patent office support in Keytruda dispute
Unpacking the Latest Options Trading Trends in Merck & Co
Financial giants have made a conspicuous bullish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE: MRK) revealed 30 unusual trades. Delving into the details, we found 60% of t...
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and pr...
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference.
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion."
Donaldson CEO Says Tariff Impact Is Immaterial, Raises Annual Profit Outlook
Donaldson Company, Inc. (NYSE: DCI) announced its third-quarter results on Tuesday. Sales rose 1.3% year over year (Y/Y) to $940.1 million, led by favorable pricing and volume growth. It missed the c...
Is Merck Stock About To Crash?
Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average reven...
MoonLake Stock Jumps 23%. Why a $3 Billion Merck Offer Could Be a Win-Win.
Merck made $3B+ offer for MoonLake earlier this year - report
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.
Merck held talks to buy Swiss biotech MoonLake for more than $3bn
US pharmaceuticals group has been looking to rebuild its pipeline before crucial cancer drug comes off-patent
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Merck Stock's Ticking Keytruda Time Bomb
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is large...
2 Dirt Cheap Dividend Stocks That Are Practically Giving Themselves Away
Even pros can't beat the market. Forecasts fail, fees pile up, and short-term thinking hurts returns. So I stick to quality dividend stocks. I found two high-conviction dividend stocks that the market...
Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda
Top 10 High-Yield Dividend Stocks
The liberation day market selloff has been entirely recovered during the month of May. Since inception, my watchlist has a CAGR of 14.81%, performing in-line with SPY and VYM, while providing a superi...
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC TROPION-...
Gilead’s Trodelvy with Merck’s Keytruda cuts disease progression/ death in breast cancer
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, acc...
KEYTRUDA (pembrolizumab) Plus Trodelvy (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progressio...
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduc...